An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

Completed · Phase 2

Conditions studied: Non-alcoholic Steatohepatitis, Fatty Liver, Fibrosis, Liver, Compensated Cirrhosis

In brief

To evaluate the safety and tolerability of Nitazoxanide (NTZ) 500mg Twice Daily (BID) after 24 weeks of treatment in patients with NASH induced Stage 2 or Stage 3 fibrosis

Key facts

Study ID

NCT03656068

Run by

Pinnacle Clinical Research, PLLC

People needed

21

Starts

2018-12-04

Expected to finish

2020-11-25

Last updated by the study team

2022-06-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females aged from 18 to 75 years inclusive the Screening Visit.
• Must provide signed written informed consent and agree to comply with the study protocol.
• Females participating in this study must be of non-childbearing potential or using highly efficient contraception for the full duration of the study
• Histological confirmation of steatohepatitis on a diagnostic liver biopsy (biopsy obtained within 6 months prior to Screening or during the Screening Period) with at least 1 in each component of the NAS (steatosis scored 0-3, ballooning degeneration scored 0-2, and lobular inflammation scored 0-3).
• Fibrosis stage of 2 or 3, according to the NASH Clinical Research Network fibrosis staging system on a diagnostic liver biopsy (biopsy obtained within 6 months prior to Screening or during the Screening Period).
• Two assessments of ALT, AST, Total bilirubin, Alkaline phosphatase (ALP), Creatine phosphokinase (CPK) will be collected during screening at least 4 weeks apart. To be eligible the second value cannot be ≥2x the first value.

You may not qualify if…

• History of efficient bariatric surgery within 5 years prior to Screening, or planned bariatric surgery in the course of the study.
• Patients with HbA1c >10.0%. If abnormal at the first Screening Visit, the HbA1c measurement can be repeated. A repeated abnormal HbA1c (HbA1c >10.0%) leads to exclusion.
• Patients with a history of clinically significant acute cardiac event within 6 months prior to Screening such as: stroke, transient ischemic attack, or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures).
• Weight loss of more than 10% within 6 months prior to Randomization.
• Patient with any history or presence of decompensated cirrhosis.
• Current or recent history (<1 year) of significant alcohol consumption. For men, significant consumption is typically defined as higher than 30 g pure alcohol per day. For women, it is typically defined as higher than 20 g pure alcohol per day.
• Current or history of other substance abuse within 1 year prior to screening.
• Pregnant or lactating females or females planning to become pregnant during the study period.
• Other well documented causes of chronic liver disease according to standard diagnostic procedures including, but not restricted to:
• Positive hepatitis B surface antigen (HBsAg)
• Positive Hepatitis C virus (HCV) RNA, (tested for in case of known cured HCV infection, or positive HCV Ab at Screening)
• Suspicion of drug-induced liver disease
• Alcoholic liver disease
• Autoimmune hepatitis
• Wilson's disease
• Primary biliary cirrhosis, primary sclerosing cholangitis
• Genetic homozygous hemochromatosis
• Known or suspected Hepatocellular Carcinoma
• History or planned liver transplant, or current Model for End-Stage Liver Disease score >15.
• Patients who cannot be contacted in case of emergency.
• Known hypersensitivity to the investigation product or any of its formulation excipients.
• Patients who are taking warfarin or other highly plasma protein-bound drugs with narrow therapeutic indices.
• Patients who are currently participating in, plan to participate in, or have participated in an investigational drug trial or medical device trial containing active substance within 30 days or five half-lives, whichever is longer, prior to Screening.
• Evidence of any other unstable or, untreated clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, neoplastic, or psychiatric disease.
• Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.

Where it is running

• Pinnacle Clinical Research — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.